Objective:This study aimed to evaluate the association between obstructive sleep apnea-hypopnea syndrome (OSAHS) and reflux esophagitis (RE).Methods:This cross-sectional study retrospectively analyzed 218 patients diagnosed with OSAHS by polysomnography (PSG) and who also had undergone gastroscopy at the First People′s Hospital of Yunnan Province from January 2021 to December 2021. The cohort comprised 91 males and 127 females, aged from 19 to 78 years (40.7±13.2). Clinical data, PSG parameters, and gastroscopy findings were collected. The prevalence of RE among OSAHS patients was calculated, potential risk factors for RE were evaluated. Differences in PSG parameters between patients with and without RE were analyzed. Statistical analyses were conducted using SPSS 26.0.Results:The prevalence of RE in OSAHS patients was 20.6% (45/218). Males had a significantly higher RE prevalence than females (31.9% vs. 12.6%, χ2=12.02, P<0.05). The difference remained significant after adjusting for confounding factors (34.9% vs. 11.1%, χ2=10.08, P<0.05). No significant variation in RE prevalence was observed across age groups. However, after adjusting for confounding factors, a significant difference was found between overweight and obese BMI groups (12.5% vs. 29.2%, χ2=4.04, P<0.05). When stratified by apnea-hypopnea index (AHI) severity, RE prevalence increased progressively in mild (7.1%), moderate (18.8%), and severe (30.1%) groups, with statistically significant differences ( χ2=11.45, P<0.05). Positive correlations were found between RE and male sex, AHI, longest apnea time (LAT), and time spent with oxygen saturation below 90% (TS90%) ( rs=0.24, 0.18, 0.17, 0.14, respectively, P<0.05). Regression analysis showed that identified male sex was the primary independent predictor of RE. Patients with RE exhibited higher AHI, TS90%, and LAT compared to those without RE ( P<0.05) .Conclusion:This single-center hospital-based study revealed a relatively high prevalence of reflux esophagitis (20.6%) among patients with OSAHS. Male sex was identified as the main independent factor associated with RE. Furthermore, RE prevalence increased with greater AHI, BMI, LAT and TS90%.

Parkinson's disease(PD)is a common progressive neurodegenerative disease mainly affecting the motor system.Various genetic factors and cellular mechanisms underlying PD have recently been discovered.Emerging evidence suggests that epigenetic modifications play a very important role in the pathogenesis,prevention,and treatment of PD.Epigenetic modification mediates genetic and environmental interactions mainly through complex interactions of DNA methylation,histone modification,and non-coding RNA,thereby affecting expression in the absence of changes in DNA sequence.In this review,we summarize the epigenetic modification mechanisms involved in the pathogenesis of Parkinson's disease.In this review,we summarize the epigenetic modification mechanisms involved in the pathogenesis of Parkinson's disease.Recent studies have found that traditional Chinese medicine can participate in the regulation of abnormal epigenetic modifications in the treatment of PD.Traditional Chinese medicine benefits from its multi-level and multi-target regulatory effects,and various traditional Chinese medicine monomers,compound prescriptions,and techniques have been evaluated,confirming that this is a promising approach for improving symptoms in PD.This review summarizes the mechanisms by which epigenetic modifications contribute to P D,explores the role of traditional Chinese medicine,and provides new ideas for clinical treatment and drug development in PD through epigenetic intervention.

Parkinson's disease(PD)is a common progressive neurodegenerative disease mainly affecting the motor system.Various genetic factors and cellular mechanisms underlying PD have recently been discovered.Emerging evidence suggests that epigenetic modifications play a very important role in the pathogenesis,prevention,and treatment of PD.Epigenetic modification mediates genetic and environmental interactions mainly through complex interactions of DNA methylation,histone modification,and non-coding RNA,thereby affecting expression in the absence of changes in DNA sequence.In this review,we summarize the epigenetic modification mechanisms involved in the pathogenesis of Parkinson's disease.In this review,we summarize the epigenetic modification mechanisms involved in the pathogenesis of Parkinson's disease.Recent studies have found that traditional Chinese medicine can participate in the regulation of abnormal epigenetic modifications in the treatment of PD.Traditional Chinese medicine benefits from its multi-level and multi-target regulatory effects,and various traditional Chinese medicine monomers,compound prescriptions,and techniques have been evaluated,confirming that this is a promising approach for improving symptoms in PD.This review summarizes the mechanisms by which epigenetic modifications contribute to P D,explores the role of traditional Chinese medicine,and provides new ideas for clinical treatment and drug development in PD through epigenetic intervention.

Objective:This study aimed to evaluate the association between obstructive sleep apnea-hypopnea syndrome (OSAHS) and reflux esophagitis (RE).Methods:This cross-sectional study retrospectively analyzed 218 patients diagnosed with OSAHS by polysomnography (PSG) and who also had undergone gastroscopy at the First People′s Hospital of Yunnan Province from January 2021 to December 2021. The cohort comprised 91 males and 127 females, aged from 19 to 78 years (40.7±13.2). Clinical data, PSG parameters, and gastroscopy findings were collected. The prevalence of RE among OSAHS patients was calculated, potential risk factors for RE were evaluated. Differences in PSG parameters between patients with and without RE were analyzed. Statistical analyses were conducted using SPSS 26.0.Results:The prevalence of RE in OSAHS patients was 20.6% (45/218). Males had a significantly higher RE prevalence than females (31.9% vs. 12.6%, χ2=12.02, P<0.05). The difference remained significant after adjusting for confounding factors (34.9% vs. 11.1%, χ2=10.08, P<0.05). No significant variation in RE prevalence was observed across age groups. However, after adjusting for confounding factors, a significant difference was found between overweight and obese BMI groups (12.5% vs. 29.2%, χ2=4.04, P<0.05). When stratified by apnea-hypopnea index (AHI) severity, RE prevalence increased progressively in mild (7.1%), moderate (18.8%), and severe (30.1%) groups, with statistically significant differences ( χ2=11.45, P<0.05). Positive correlations were found between RE and male sex, AHI, longest apnea time (LAT), and time spent with oxygen saturation below 90% (TS90%) ( rs=0.24, 0.18, 0.17, 0.14, respectively, P<0.05). Regression analysis showed that identified male sex was the primary independent predictor of RE. Patients with RE exhibited higher AHI, TS90%, and LAT compared to those without RE ( P<0.05) .Conclusion:This single-center hospital-based study revealed a relatively high prevalence of reflux esophagitis (20.6%) among patients with OSAHS. Male sex was identified as the main independent factor associated with RE. Furthermore, RE prevalence increased with greater AHI, BMI, LAT and TS90%.

Parkinson's disease is a neurodegenerative disease associated with abnormal copper metabolism in the brain,which leads to misfolding and aggregation of α-synuclein-copper complexes,which is an important pathological sign of Parkinson's disease.Copper metabolism,i.e.,cellular metabolic processes involving copper ions,is closely related to the pathogenesis of α-synuclein aggregation,dopamine metabolism,mitochondrial dysfunction,oxidative stress,and ferroptosis in Parkinson's disease.In this review,we summarize the molecular metabolic mechanism of copper toxicity by studying the pathological role of copper metabolism in Parkinson's disease,to support our further understanding of the mechanism of action and drug development.

Background::While type 2 diabetes mellitus (T2DM) is considered a putative causal risk factor for coronary artery disease (CAD), the intrinsic link underlying T2DM and CAD is not fully understood. We aimed to highlight the importance of integrated care targeting both diseases by investigating the phenotypic and genetic relationships between T2DM and CAD.Methods::We evaluated phenotypic associations using data from the United Kingdom Biobank ( N = 472,050). We investigated genetic relationships by leveraging genomic data conducted in European ancestry for T2DM, with and without adjustment for body mass index (BMI) (T2DM: Ncase/ Ncontrol = 74,124/824,006; T2DM adjusted for BMI [T2DM adjBMI]: Ncase/ Ncontrol = 50,409/523,897) and for CAD ( Ncase/ Ncontrol = 181,522/984,168). We performed additional analyses using genomic data conducted in multiancestry individuals for T2DM ( Ncase/ Ncontrol = 180,834/1,159,055). Results::Observational analysis suggested a bidirectional relationship between T2DM and CAD (T2DM→CAD: hazard ratio [HR] = 2.12, 95% confidence interval [CI]: 2.01–2.24; CAD→T2DM: HR = 1.72, 95% CI: 1.63–1.81). A positive overall genetic correlation between T2DM and CAD was observed ( rg = 0.39, P = 1.43 × 10 -75), which was largely independent of BMI (T2DM adjBMI–CAD: rg = 0.31, P = 1.20 × 10 –36). This was corroborated by six local signals, among which 9p21.3 showed the strongest genetic correlation. Cross-trait meta-analysis replicated 101 previously reported loci and discovered six novel pleiotropic loci. Mendelian randomization analysis supported a bidirectional causal relationship (T2DM→CAD: odds ratio [OR] = 1.13, 95% CI: 1.11-1.16; CAD→T2DM: OR = 1.12, 95% CI: 1.07-1.18), which was confirmed in multiancestry individuals (T2DM→CAD: OR = 1.13, 95% CI: 1.10-1.16; CAD→T2DM: OR = 1.08, 95% CI: 1.04-1.13). This bidirectional relationship was significantly mediated by systolic blood pressure and intake of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, with mediation proportions of 54.1% (95% CI: 24.9-83.4%) and 90.4% (95% CI: 29.3-151.5%), respectively. Conclusion::Our observational and genetic analyses demonstrated an intrinsic bidirectional relationship between T2DM and CAD and clarified the biological mechanisms underlying this relationship.

Objective:To assess the clinical effectiveness and safety of Omalizumab for treating pediatric allergic asthma in real world in China.Methods:The clinical data of children aged 6 to 11 years with allergic asthma who received Omalizumab treatment in 17 hospitals in China between July 6, 2018 and September 30, 2020 were retrospectively analyzed.Such information as the demographic characteristics, allergic history, family history, total immunoglobulin E (IgE) levels, specific IgE levels, skin prick test, exhaled nitric oxide (FeNO) levels, eosinophil (EOS) counts, and comorbidities at baseline were collected.Descriptive analysis of the Omalizumab treatment mode was made, and the difference in the first dose, injection frequency and course of treatment between the Omalizumab treatment mode and the mode recommended in the instruction was investigated.Global Evaluation of Treatment Effectiveness (GETE) analysis was made after Omalizumab treatment.The moderate-to-severe asthma exacerbation rate, inhaled corticosteroid (ICS) dose, lung functions were compared before and after Omalizumab treatment.Changes in the Childhood Asthma Control Test (C-ACT) and Pediatric Asthma Quality of Life Questionnaire (PAQLQ) results from baseline to 4, 8, 12, 16, 24, and 52 weeks after Omalizumab treatment were studied.The commodity improvement was assessed.The adverse event (AE) and serious adverse event (SAE) were analyzed for the evaluation of Omalizumab treatment safety.The difference in the annual rate of moderate-to-severe asthma exacerbation and ICS reduction was investigated by using t test.The significance level was set to 0.05.Other parameters were all subject to descriptive analysis.A total of 200 allergic asthma patients were enrolled, including 75.5% ( n=151) males and 24.5% ( n=49) females.The patients aged (8.20±1.81) years. Results:The median total IgE level of the 200 patients was 513.5 (24.4-11 600.0) IU/mL.Their median treatment time with Omalizumab was 112 (1-666) days.Their first dose of Omalizumab was 300 (150-600) mg.Of the 200 cases, 114 cases (57.0%) followed the first Omalizumab dosage recommended in the instruction.After 4-6 months of Omalizumab treatment, 88.5% of the patients enrolled ( n=117) responded to Omalizumab.After 4 weeks of treatment with Omalizumab, asthma was well-controlled, with an increased C-ACT score [from (22.70±3.70) points to (18.90±3.74) points at baseline]. Four-six months after Omalizumab administration, the annual rate of moderate-to-severe asthma exacerbation had a reduction of (2.00±5.68) per patient year( t=4.702 5, P<0.001), the median ICS daily dose was lowered [0 (0-240) μg vs. 160 (50-4 000) μg at baseline] ( P<0.001), the PAQLQ score was improved [(154.90±8.57) points vs. (122.80±27.15) points at baseline], and the forced expiratory volume in one second % predicted (FEV 1%pred) was increased [(92.80±10.50)% vs. (89.70±18.17)% at baseline]. In patients with available evaluations for comorbidities, including allergic rhinitis, atopic dermatitis or eczema, urticaria, allergic conjunctivitis and sinusitis, 92.8%-100.0% showed improved symptoms.A total of 124 AE were reported in 58 (29.0%) of the 200 patients, and the annual incidence was 0(0-15.1) per patient year.In 53 patients who suffered AE, 44 patients (83.0%) and 9 patients (17.0%) reported mild and moderate AE, respectively.No severe AE were observed in patients.The annual incidence of SAE was 0(0-1.9) per patient year.Most common drug-related AE were abdominal pain (2 patients, 1.0%) and fever (2 patients, 1.0%). No patient withdrew Omalizumab due to AE. Conclusions:Omalizumab shows good effectiveness and safety for the treatment of asthma in children.It can reduce the moderate-to-severe asthma exacerbation rate, reduce the ICS dose, improve asthma control levels, and improve lung functions and quality of life of patients.

H 1-antihistamines are widely used in the treatment of various allergic diseases, but there are still many challenges in the safe and rational use of H 1-antihistamines in pediatrics, and there is a lack of guidance on the prescription review of H 1-antihistamines for children.In this paper, suggestions are put forward from the indications, dosage, route of administration, pathophysiological characteristics of children with individual difference and drug interactions, so as to provide reference for clinicians and pharmacists.

Objective:To explore the effect of solution-focused model psychological intervention on disability acceptance of ischemic stroke patients.Methods:From May to July 2020, 200 patients with ischemic stroke who were admitted to the Neurology Department of the Second Hospital of Hebei Medical University were selected as the study subject by convenience sampling. The patients were randomly divided into the control group and the observation group by the envelope method, with 100 cases in each group. The control group was given routine nursing, while the observation group received solution-focused model psychological intervention on the basis of routine nursing. The Acceptance of Disability Scale (ADS) and Stroke Specific Quality of Life Scale (SS-QOL) were used to compare the disability acceptance and quality of life at admission, three months and six months after discharge in the two groups. There were two cases lost in the observation group and two cases lost in the control group, and 98 patients were included in the final observation group and the control group respectively.Results:There was no statistical difference in the scores of ADS and SS-QOL between the two groups at admission ( P>0.05) . At three and six months after discharge, the scores of ADS and SS-QOL of patients in the observation group were higher than those at admission, and the scores in the observation group were higher than those in the control group, with statistically significant differences ( P<0.01) . Conclusions:The solution-focused model psychological intervention can improve the disability acceptance and quality of life of stroke patients, which is worthy of clinical application.

Objective: To explore the epidemiological characteristics of mortality of accidental injury children aged 5-19 years in Yunnan Province during 2015-2019, to provide further evidence for reducing accidental mortality in children. Methods: The mortality cases of accidental injury by gender, age groups, and causes among children and adolescents in Yunnan Province during 2015 to 2019 were analyzed retrospectively. Poisson regression model was used to estimate the trend of mortality. Chi square test was used to compare the differences of mortality by gender and age groups. Results: During 2015 to 2019, the mortality rate of accidental injury in children and adolescents aged 5-19 years in Yunnan Province decreased from 19.15/10 5 in 2015 to 18.35/10 5 in 2019 (Z=-3.36, P <0.01). The mortality rate of all types of accidental injuries in male was higher than that in female ( χ 2=867.01, 11.69 , 147.60, 190.34, 7.23, 702.97, P <0.05). The top three causes of fatal accidental injuries included road traffic accidents, drowning and falls. Except for accidental falls, the mortality rate of other causes in the 15-19 age group was significantly higher than that in the age of 5-9 years and 10-14 years groups ( χ 2=764.47, 75.91, 31.75, 9.24, 114.96, 327.64, P <0.05). The top three traffic accidents were happened among motorcyclists, light trucks or caravans and cars, accounting for 27.83%, 10.57% and 7.90% respectively. Conclusion Targeted measures should be taken continuously according to the characteristics of children and adolescents in different regions, age groups and gender to reduce the incidence and mortality of accidental injuries among children.